Meeting
2014 ASCO Annual Meeting
Delivery of peri-operative chemotherapy for muscle-invasive bladder cancer (MIBC) in routine clinical practice: Does regimen and timing matter?
Authors
Christopher M. Booth
Division of Cancer Care & Epidemiology, Cancer Research Institute, Queen's University, Kingston, ON, Canada
Christopher M. Booth , D. Robert Siemens , Yingwei Peng , Ian Tannock , William J. Mackillop
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary (Nonprostate) Cancer
Track
Genitourinary Cancer
Sub Track
Bladder Cancer
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 4537)
DOI
10.1200/jco.2014.32.15_suppl.4537
Abstract #
4537
Poster Bd #
105
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
Bladder-sparing treatment for muscle-invasive bladder carcinoma: A single-center, single-arm clinical study of sequential neoadjuvant chemotherapy followed by tislelizumab neoadjuvant immunotherapy.
First Author: Yu Zeng
Poster
2022 ASCO Annual Meeting
S1314 correlative analysis of ATM, RB1, ERCC2, and FANCC mutations and pathologic complete response (pT0) at cystectomy after neoadjuvant chemotherapy (NAC) in patients with muscle invasive bladder cancer (MIBC): Implications for bladder preservation.
First Author: Elizabeth R. Plimack
Poster
2020 ASCO Virtual Scientific Program
Dissecting outcomes of patients (pts) with <ypT2N0 disease after neoadjuvant chemotherapy (NAC) for muscle invasive bladder cancer (MIBC): Results from a large, international, multicenter collaboration.
First Author: Praful Ravi
Poster
2019 ASCO Annual Meeting
Increasing use of neoadjuvant chemotherapy (NAC) in muscle-invasive bladder cancer (MIBC): Prognostic impact of non-standard of care (SOC) regimens.
First Author: Yaw A. Nyame